Considering the Applications of On-Body Injector for Myeloma in Community Practice

Joseph Mikhael, MD, MEd, discusses how the FDA approval of subcutaneous isatuximab (Sarclisa Escena) utilizing an on-body injector (OBI) offers potential for workflow efficiencies and operational flexibility for community oncology practices. Historically, intravenous infusions required extended clinic stays and continuous resources. Subcutaneous administration using manual injection reduces infusion times, but they still require a nurse to remain physically present and occupied for the entire duration of the administration. In contrast, the automated on-body injector fundamentally shifts this dynamic by offering an autonomous delivery model that optimizes the process.

The primary advantage of the on-body injector in this setting is its ability to free up nursing staff, although they still need to maintain patient oversight. Once healthcare personnel apply the prefilled device to the patient's skin and initiate delivery, constant one-on-one direct supervision is no longer strictly required throughout the administration window. Nurses can safely step away to attend to other clinical duties, manage separate patients, or fulfill administrative responsibilities, returning to monitor the patient. This hands-off capability significantly smooths clinic operations, reduces staffing bottlenecks, and maximizes the efficiency of the clinical care team.

Furthermore, the on-body injector introduces unprecedented flexibility regarding where and how treatment is administered within a community practice. Because the automated device eliminates the necessity for dedicated intravenous infusion chairs and continuous one-on-one nursing oversight, administrations can easily take place in non-traditional clinic areas outside the main infusion suite. Although the regulatory approval permits both manual subcutaneous pushes and on-body injector delivery, Mikhael anticipates that the vast majority of community providers and patients will naturally favor the on-body injector. By accommodating the needs of clinic workflows and removing the logistical burdens of intravenous lines, this technology establishes a highly adaptable and patient-friendly delivery paradigm for community oncology.